On Monday,

周一，

Arrowhead Pharmaceuticals, Inc.

箭头制药公司

ARWR

ARWR

released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various

公布了ARO-C3的1/2期研究第二部分的顶线结果，该公司的研究性RNA干扰（RNAi）治疗药物旨在减少肝脏补体成分3（C3）的生成，作为各种疾病的潜在疗法。

complement-mediated diseases

补体介导的疾病

.

。

ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential treatment for various complement-mediated renal diseases.

ARO-C3旨在减少肝细胞产生补体C3，作为治疗各种补体介导的肾脏疾病的潜在方法。

The dysregulated activity of the complement system can contribute to tissue injury and the progression of the disease. By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal diseases by modulating the activation of the complement cascade.

补体系统的失调活动可能导致组织损伤和疾病进展。通过沉默C3，研究中的ARO-C3有可能通过调节补体级联的激活来治疗补体介导的肾脏疾病。

Also Read:

另请阅读：

Veren Soars On Whitecap Merger Deal: Details

Veren因与Whitecap的合并交易而飙升：详情

The company plans to present additional results at a

公司计划在会议上展示更多结果，

medical meeting in 2025

2025年的医学会议

.

。

Select Phase 1/2 Study Results

选择第一/二期研究结果

Pharmacodynamic effects: Maximum mean reduction in C3 of 89% and mean sustained reduction of greater than 87% from baseline through week 24.

药效学效应：C3最大平均降低89%，从基线到第24周平均持续降低超过87%。

Maximum mean reduction in serum AH50 (alternative pathway hemolytic assay) of 85% and mean sustained reduction greater than 76%.

血清AH50（替代途径溶血试验）最大平均降低85%，平均持续降低大于76%。

Maximum mean reduction in Wieslab AP (alternative pathway) of 100% and mean sustained reduction greater than 89%.

Wieslab AP（替代途径）最大平均减少100%，平均持续减少大于89%。

Duration of effect supportive of once every three months or less frequent subcutaneous dosing in later-stage studies

在后期研究中，支持每三个月或更少频率的皮下给药的效果持续时间

Effects on proteinuria (too much protein in the urine): The mean reduction in spot UPCR was 41%, and the maximum individual reduction was 89%.

对蛋白尿（尿液中蛋白质过多）的影响：斑点尿蛋白肌酐比值 (UPCR) 的平均降幅为 41%，最大个体降幅为 89%。

In January, the U.S. Food and Drug Administration accepted Arrowhead Pharmaceuticals’ New Drug Application for investigational plozasiran for familial chylomicronemia syndrome, a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an .

今年 1 月，美国食品和药物管理局接受了 Arrowhead Pharmaceuticals 针对家族性乳糜微粒血症综合征（一种严重且罕见的遗传病）研究性药物 plozasiran 的新药申请。FDA 提供了 2025 年 11 月 18 日作为《处方药使用者费用法案》（PDUFA）的行动日期，并表示目前不打算召开 。

advisory committee meeting

顾问委员会会议

.

。

In February, Arrowhead Pharmaceuticals closed a global licensing and collaboration agreement with

今年 2 月，Arrowhead Pharmaceuticals 与

Sarepta Therapeutics Inc

萨雷普塔治疗公司

. Arrowhead receives a $500 million upfront payment and $325 million

Arrowhead获得5亿美元的预付款和3.25亿美元

through Sarepta stock

通过萨雷普塔股票

.

。

Price Action:

价格行为:

ARWR stock is down 8.72% at $15.49 at the last check Monday.

ARWR股票在周一最后一次检查时下跌了8.72%，至15.49美元。

Read Next:

接下来阅读：

Pfizer’s COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations

辉瑞新冠疫苗合作伙伴BioNTech公布第四季度盈利，但2025年预期指引未达预期

Photo via Shutterstock.

通过Shutterstock拍摄的照片。

ARWR

ARWR

Arrowhead Pharmaceuticals Inc

箭头制药公司

$15.54

15.54美元

-8.43

-8.43

%

%

Stock Score Locked: Edge Members Only

库存评分已锁定：仅限Edge会员

Benzinga Rankings give you vital metrics on any stock – anytime.

Benzinga排名为您提供任何股票的关键指标——随时。

Unlock Rankings

解锁排名

Edge Rankings

边缘排名

Momentum

动量

12.08

12.08

Growth

成长

98.78

98.78

Quality

质量

-

-

Value

值

1.10

1.10

Price Trend

价格趋势

Short

短的

Medium

中等

Long

长

Overview

概述

SRPT

SRPT

Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

$100.28

100.28美元

-2.67

-2.67

%

%

Market News and Data brought to you by Benzinga APIs

由Benzinga API提供的市场新闻和数据

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

© 2025 Benzinga.com. Benzinga 不提供投资建议。保留所有权利。